The Uromigos Episode 158: ASCO GU 2022 PROpel Phase III Olaparib and Abiraterone in mCRPC

By The Uromigos - Last Updated: November 11, 2022

Dr. Fred Saad describes the results of the PROpel Phase III trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC.

Post Tags:Uromigos-ASCO GUUromigos-Prostate Cancer
Advertisement

Related Podcasts

Episode 374: Mechanisms of HIF Resistance
Uromigos-Kidney Cancer
Episode 372: FDA Accelerated Approval Process
Episode 371: TROPiCS-04 Results From ESMO Asia
Uromigos-Bladder Cancer
Episode 370: Artificial Intelligence in Medical Oncology
Episode 369: Paper of the Month With Bishoy Faltas
Uromigos-Bladder Cancer
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |